Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2026)

Indivior Pharmaceuticals has reported Other Non-Current Assets over the past 6 years, most recently at $26.0 million for Q1 2026.

  • For Q1 2026, Other Non-Current Assets fell 33.33% year-over-year to $26.0 million; the TTM value through Mar 2026 reached $26.0 million, down 33.33%, while the annual FY2025 figure was $27.0 million, 30.77% down from the prior year.
  • Other Non-Current Assets for Q1 2026 was $26.0 million at Indivior Pharmaceuticals, down from $27.0 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $95.0 million in Q3 2023 and troughed at $26.0 million in Q1 2026.
  • A 5-year average of $40.5 million and a median of $38.0 million in 2022 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 66.32% in 2024 and later skyrocketed 33.33% in 2025.
  • Year by year, Other Non-Current Assets stood at $38.0 million in 2022, then decreased by 5.26% to $36.0 million in 2023, then rose by 8.33% to $39.0 million in 2024, then plummeted by 30.77% to $27.0 million in 2025, then decreased by 3.7% to $26.0 million in 2026.
  • Business Quant data shows Other Non-Current Assets for INDV at $26.0 million in Q1 2026, $27.0 million in Q4 2025, and $27.0 million in Q3 2025.